Indications |
Oral Oedema Adult: Initially, 100 mg daily, may adjust dose according to response up to 400 mg daily. Child: Neonates: 1-2 mg/kg daily; 1 mth-12 yr: 1-3 mg/kg daily; 12-18 yr: 50-100 mg daily. To be given in 1-2 divided doses. Elderly: Initially, 25-50 mg/day in 1-2 divided doses, may increase by 25-50 mg every 5 days when necessary.
Oral Hepatic cirrhosis with ascites and oedema Adult: Depending on urinary sodium/potassium ratio: If >1: Initially, 100 mg daily and if <1: Initially, 200-400 mg daily. Child: Neonate: 1-2 mg/kg daily (Max: 7 mg/kg daily in resistant ascites); 1 mth-12 yr: 1-3 mg/kg daily (Max: 9 mg/kg daily in resistant ascites); 12-18 yr: 50-100 mg daily (Max: 400 mg daily in resistant ascites). To be given in 2 divided doses. Elderly: Dosing adjustment may be required.
Oral Diagnosis of primary hyperaldosteronism Adult: 400 mg daily for 3-4 wk. Correction of serum potassium levels and hypertension gives the presumptive evidence for the diagnosis of primary aldosteronism. Elderly: Dosing adjustment may be required.
Oral Preoperative management of hyperaldosteronism Adult: 100-400 mg daily. Long term maintenance in the absence of surgery: May initiate at 400 mg daily and maintain at 100-300 mg daily; lowest effective dose should be used. Elderly: Dosing adjustment may be required.
Oral Hypertension Adult: As monotherapy: Usual dose range: 25-50 mg daily, may increase up to 100 mg daily if needed. Elderly: Initially, 25-50 mg/day in 1-2 divided doses, may increase by 25-50 mg every 5 days when necessary.
Oral Severe congestive heart failure Adult: For patients receiving an ACE inhibitor and a loop diuretic with or without a cardiac glycoside: Initially, 12.5-25 mg daily. May increase to 50 mg daily after 8 wk of treatment depending on response. Child: Neonates: 1-2 mg/kg daily; 1 mth-12 yr: 1-3 mg/kg daily; 12-18 yr: 50-100 mg daily. To be given in 1-2 divided doses. Elderly: Dosing adjustment may be required.
Oral Diuretic-induced hypokalaemia Adult: 25-100 mg daily. Child: Neonates: 1-2 mg/kg daily; 1 mth-12 yr: 1-3 mg/kg daily; 12-18 yr: 50-100 mg daily. To be given in 1-2 divided doses. Elderly: Dosing adjustment may be required.
Oral Hirsutism Adult: 50-200 mg daily. Elderly: Dosing adjustment may be required.
|
||||||||||||||||||||||||||||||||||||||||||||||||
Contraindications |
Anuria, hyperkalaemia, acute or progressive renal insufficiency. Addison's disease. | ||||||||||||||||||||||||||||||||||||||||||||||||
Warnings / Precautions |
Patients at risk of developing hyperkalaemia and acidosis; monitor serum electrolytes; renal and hepatic impairment; DM; elderly; pregnancy. | ||||||||||||||||||||||||||||||||||||||||||||||||
Adverse Reactions |
Fluid or electrolyte imbalance, gynaecomastia, GI upset, drowsiness, headache, hyponatraemia; tachycardia, hypotension, oliguria, hyperkalaemia; confusion, weakness, paraesthesia, hirsutism, mental disturbances, menstrual irregularities, loss of libido and impotence. Potentially Fatal: Fatal hyperkalaemia in combination with ACE inhibitors and previous renal impairment; agranulocytosis. |
||||||||||||||||||||||||||||||||||||||||||||||||
Overdose Reactions |
Acute overdosage may result in drowsiness, mental confusion, maculopapular or erythematous rash, nausea, vomiting, dizziness or diarrhoea. Hyperkalemia may occur, especially in patients with impaired renal function. Induce vomiting or evacuate the stomach by lavage. Supportive treatment to maintain hydration, electrolyte balance and vital functions. For hyperkalaemia, cationic exchange resins such as sodium polystyrene sulfonate may be given orally or rectally. Persistent hyperkalemia may require dialysis. | ||||||||||||||||||||||||||||||||||||||||||||||||
Drug Interactions |
Sodium excretion effect may be inhibited by aspirin. May reduce ulcer-healing properties of carbenoxolone. Increased risk of nephrotoxicity when used with NSAIDs or ciclosporin. Hyperkalaemia may occur if given with potassium supplements, ACE inhibitors, angiotensin II antagonists, NSAIDs, ciclosporin or trilostane. May increase risk of orthostatic hypotension when used with barbiturates, narcotics or alcohol. May reduce vascular responsiveness to pressor amines. May increase half-life of digoxin. Potentially Fatal: Increased risk of lithium toxicity when used concurrently. See Below for More spironolactone Drug Interactions |
||||||||||||||||||||||||||||||||||||||||||||||||
Lab Interactions |
Interferes with fluorometric measurements of plasma cortisol, immunoassays for serum digoxin, and estimations of 17-ketosteroids and 17-ketogenic steroids. | ||||||||||||||||||||||||||||||||||||||||||||||||
Food Interactions |
Improved absorption if taken after food. | ||||||||||||||||||||||||||||||||||||||||||||||||
Mechanism of Actions |
Spironolactone acts on the distal renal tubules as a competitive antagonist of aldosterone. It increases the excretion of sodium chloride and water while conserving potassium and hydrogen ions. Absorption: Well absorbed from the GI tract after oral admin with a bioavailability of 90%. Distribution: About 90% bound to plasma proteins. Metabolism: Extensively metabolised. Excretion: Mainly excreted in the urine, some in the faeces, as metabolites. |
||||||||||||||||||||||||||||||||||||||||||||||||
Administration |
Should be taken with food. |
||||||||||||||||||||||||||||||||||||||||||||||||
Storage Conditions |
Oral: Store <25°C. | ||||||||||||||||||||||||||||||||||||||||||||||||
ATC Classification |
C03DA01 - spironolactone ; Belongs to the class of aldosterone antagonists. Used as potassium-sparing diuretics. | ||||||||||||||||||||||||||||||||||||||||||||||||
Storage |
Oral: Store <25°C. | ||||||||||||||||||||||||||||||||||||||||||||||||
Available As |
|
Spironolactone
Post Review about Spironolactone Click here to cancel reply.
Spironolactone Containing Brands
Spironolactone is used in following diseases
Drug - Drug Interactions of Spironolactone
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.